VBLT News and Press, Vascular Biogenics Ltd. From 06/04/20

VBL Therapeutics (NASDAQ: VBLT ) announces new data on its proprietary anti-MOSPD2 antibodies in rheumatoid arthritis (RA). The results are being virtually presented at EULAR. More news on: Vascular Biogenics Ltd., Healthcare stocks news, Stocks on the move, Read more ...

TEL AVIV, Israel, June 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis (RA). VBL's study entitled “MO...

OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recom...

TEL AVIV, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) announced today that new data suggesting the potential of its proprietary bi-specific antibodies for immune-mediated targeting of solid tumors will be presented at the Annual American Association for Cancer...

Vascular Biogenics Ltd. (VBLT) Q1 2020 Earnings Conference Call May 14, 2020 08:30 AM ET Company Participants Michael Wood - Investor Relations, LifeSci Advisors Dror Harats - Chief Executive Officer Amos Ron - Chief Financial Officer Conference Call Participants Jonathan A...

VBL Therapeutics (NASDAQ: VBLT ): Q1 GAAP EPS of -$0.15 beats by $0.02 . More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

TEL AVIV, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. “We reached an important milestone in our development of VB-111 in ovarian cancer with ...

TEL AVIV, Israel, May 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-m...

VBL Therapeutics (NASDAQ: VBLT ) has closed its previous registered direct offering of 6,349,208 ordinary shares at a purchase price of $1.575/share and unregistered warrants to purchase same number of ordinary shares, for gross proceeds of ~$10M. More news on: Vascular Biogenics Lt...

TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offeri...